Get the Stockscreener App
59.96
0.02%
0.010
After Hours:
59.96
Longboard Pharmaceuticals Inc stock is traded at $59.96, with a volume of 864.70K.
It is up +0.02% in the last 24 hours and up +0.60% over the past month.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
See More
Previous Close:
$59.95
Open:
$59.96
24h Volume:
864.70K
Relative Volume:
0.52
Market Cap:
$2.34B
Revenue:
-
Net Income/Loss:
$-76.34M
P/E Ratio:
-23.50
EPS:
-2.5513
Net Cash Flow:
$-65.93M
1W Performance:
+0.32%
1M Performance:
+0.60%
6M Performance:
+218.94%
1Y Performance:
+1,407%
1-Day Range:
$59.94
$59.98
1-Week Range:
$59.76
$59.98
52-Week Range:
$3.60
$59.98
Longboard Pharmaceuticals Inc Stock (LBPH) Company Profile
Name
Longboard Pharmaceuticals Inc
Sector
Industry
Phone
619-592-9775
Address
4275 EXECUTIVE SQUARE, LA JOLLA
Compare LBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBPH
Longboard Pharmaceuticals Inc
|
59.96 | 2.34B | 0 | -76.34M | -65.93M | -2.5513 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Longboard Pharmaceuticals Inc Stock (LBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Initiated | Truist | Buy |
| Jul-01-24 | Reiterated | Cantor Fitzgerald | Overweight |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Feb-16-24 | Initiated | Citigroup | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-27-23 | Initiated | B. Riley Securities | Buy |
| Apr-07-21 | Initiated | Evercore ISI | Outperform |
| Apr-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-21 | Initiated | Citigroup | Buy |
| Apr-06-21 | Initiated | Guggenheim | Buy |
View All
Longboard Pharmaceuticals Inc Stock (LBPH) Latest News
Longboard Pharmaceuticals stock soars to all-time high of $59.96 By Investing.com - Investing.com UK
KBC Group NV Acquires New Position in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - Defense World
Jennison Associates LLC Sells 34,440 Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Brokerages Set Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Price Target at $59.56 - MarketBeat
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MARX, BRKH, MNTX and LPBH - GlobeNewswire Inc.
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage - MSN
299,156 Shares in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Bought by Braun Stacey Associates Inc. - MarketBeat
Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies - Marketscreener.com
LBPHLongboard Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs) - Business Wire
Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan
Longboard Pharmaceuticals Advances Neurological Treatments - TipRanks
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - BioSpace
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FMR LLC Reduces Stake in Longboard Pharmaceuticals Inc - GuruFocus.com
Longboard Pharma Reports Strong Q3, Advances Phase 3 Trial Amid Lundbeck Acquisition Deal | LBPH Stock News - StockTitan
How the (LBPH) price action is used to our Advantage - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Longboard Pharmace - GuruFocus.com
Longboard Pharmaceuticals granted Orphan Drug Designation for bexicaserin - TipRanks
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Position Increased by Emerald Advisers LLC - MarketBeat
Longboard Pharmaceuticals (NASDAQ:LBPH) Hits New 1-Year High – Here’s What Happened - Defense World
Longboard Pharmaceuticals stock soars to all-time high of $59.95 By Investing.com - Investing.com South Africa
Longboard Pharmaceuticals (NASDAQ:LBPH) Reaches New 52-Week HighShould You Buy? - MarketBeat
500: Something went wrong - Investing.com
Longboard Pharmaceuticals Inc options imply 0.8% move in share price post-earnings - TipRanks
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc.LBPH - Business Wire
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Given Consensus Rating of “Hold” by Analysts - Defense World
Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal - MSN
(LBPH) Trading Signals - Stock Traders Daily
B. Riley Offloads Great American To Oaktree To Cut Debt - Finimize
Longboard Pharmaceuticals stock soars to all-time high of $59.48 By Investing.com - Investing.com Australia
Longboard Pharmaceuticals (NASDAQ:LBPH) Hits New 1-Year HighStill a Buy? - MarketBeat
Longboard Pharmaceuticals stock soars to all-time high of $59.48 - Investing.com India
$DRUG 5,900% Weekly Surge Turns Attention. Cybin ($CYBN) Rallying 23% This Week In Anticipation For Major Milestones - FinanceFeeds
Longboard Pharmaceuticals (NASDAQ:LBPH) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
The week in pharma: action, reaction and insight – week to October 19 | Pharmaceutical | The Pharmaletter - The Pharma Letter
Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company - MSN
Longboard Pharmaceuticals Stock Soars 51%. It’s Being Bought for $2.6 Billion. - MSN
Longboard soars as Lundbeck to buy company for equity value of $2.6B - MSN
Longboard Pharmaceuticals Strikes $2.6 Billion Deal to Be Acquired by Lundbeck - MSN
SG Americas Securities LLC Buys Shares of 10,514 Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump - MSN
Taxation With Representation: Baker, Simpson, Ropes - Law360
Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist - Psychedelic Alpha
HC Wainwright Reiterates Neutral Rating for Longboard Pharmaceuticals (NASDAQ:LBPH) - Defense World
Longboard Pharmaceuticals CMO sells $983,936 in stock By Investing.com - Investing.com South Africa
Randall Kaye Sells 16,667 Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Stock - MarketBeat
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc.LBPH - The Malaysian Reserve
Longboard Pharmaceuticals (NASDAQ:LBPH) Lowered to Hold at Wedbush - MarketBeat
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52% - MSN
Longboard Pharmaceuticals Inc Stock (LBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longboard Pharmaceuticals Inc Stock (LBPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lind Kevin Robert | CEO |
Nov 13 '24 |
Option Exercise |
3.12 |
12,808 |
40,002 |
443,740 |
| Kaye Randall | CMO |
Oct 15 '24 |
Option Exercise |
4.35 |
16,667 |
72,501 |
34,587 |
| Kaye Randall | CMO |
Oct 15 '24 |
Sale |
59.03 |
16,667 |
983,936 |
17,920 |
| Kaye Randall | CMO |
Sep 16 '24 |
Option Exercise |
4.35 |
16,666 |
72,497 |
34,586 |
| Kaye Randall | CMO |
Sep 16 '24 |
Sale |
31.64 |
16,666 |
527,318 |
17,920 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):